Skip to main content
Top
Published in: Annals of Nuclear Medicine 2/2011

01-02-2011 | Original Article

Determination of the survival rate in patients with congestive heart failure stratified by 123I-MIBG imaging: a meta-analysis from the studies performed in Japan

Authors: Yoichi Kuwabara, Nagara Tamaki, Tomoaki Nakata, Shohei Yamashina, Junichi Yamazaki

Published in: Annals of Nuclear Medicine | Issue 2/2011

Login to get access

Abstract

Background

The goals of this meta-analysis were to determine survival rates in patients with heart failure (HF) assessed by 123I-MIBG imaging results using recently published studies and to determine the prognostic value of 123I-MIBG imaging.

Methods

We reviewed published cohort studies carried out in Japan that compared the prognosis of patients with their 123I-MIBG activity quantified as late heart-to-mediastinum ratio (H/M) or washout rate by performing a PubMed search for articles in English up to December 2006. Studies were selected if they analyzed a clearly defined lethal outcome (cardiovascular death) using life tables to estimate the odds ratio at 24 months after enrollment.

Results

Of 158 articles related to cardiac 123I-MIBG, seven referred to studies that met the inclusion criteria: 5 evaluated H/M via 123I-MIBG in a total of 866 patients and 4 calculated washout rate in a total of 491 patients. A low H/M indicated a high risk of cardiac death: pooled odds ratio, 5.2; 95% confidence interval (CI) of 3.1–5.7. A high washout was also associated with lethal events with a pooled odds ratio of 2.8 (CI: 1.6–5.0). The association between washout and cardiac death was heterogeneous (Chi-square = 11.0, P < 0.02), whereas that between late H/M and fatal events was homogeneous (Chi-square = 2.3, P = no significance).

Conclusion

This meta-analysis of published studies of 123I-MIBG studies conducted in Japan indicated that both a decreased cardiac 123I-MIBG activity (H/M) and an increased washout rate are indicative of a poor prognosis in patients with chronic heart failure.
Literature
1.
go back to reference Wieland DM, Rosenspire KC, Hutchins GD, Van Dort M, Rothley JM, Mislankar SG, et al. Neuronal mapping of the heart with 6-[18F]fluorometaraminol. J Med Chem. 1990;33:956–64.CrossRefPubMed Wieland DM, Rosenspire KC, Hutchins GD, Van Dort M, Rothley JM, Mislankar SG, et al. Neuronal mapping of the heart with 6-[18F]fluorometaraminol. J Med Chem. 1990;33:956–64.CrossRefPubMed
2.
go back to reference Rosenspire KC, Haka MS, Van Dort ME, Jewett DM, Gildersleeve DL, Schwaiger M, et al. Synthesis and preliminary evaluation of carbon-11-meta-hydroxyephedrine: a false transmitter agent for heart neuronal imaging. J Nucl Med. 1990;31:1328–34.PubMed Rosenspire KC, Haka MS, Van Dort ME, Jewett DM, Gildersleeve DL, Schwaiger M, et al. Synthesis and preliminary evaluation of carbon-11-meta-hydroxyephedrine: a false transmitter agent for heart neuronal imaging. J Nucl Med. 1990;31:1328–34.PubMed
3.
go back to reference Raffel DM, Corbett JR, del Rosario RB, Gildersleeve DL, Chiao PC, Schwaiger M, et al. Clinical evaluation of carbon-11-phenylephrine: MAO-sensitive marker of cardiac sympathetic neurons. J Nucl Med. 1996;37:1923–31.PubMed Raffel DM, Corbett JR, del Rosario RB, Gildersleeve DL, Chiao PC, Schwaiger M, et al. Clinical evaluation of carbon-11-phenylephrine: MAO-sensitive marker of cardiac sympathetic neurons. J Nucl Med. 1996;37:1923–31.PubMed
4.
go back to reference Degrado TR, Zalutsky MR, Vaidyanathan G. Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart. Nucl Med Biol. 1995;22:1–12.CrossRefPubMed Degrado TR, Zalutsky MR, Vaidyanathan G. Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart. Nucl Med Biol. 1995;22:1–12.CrossRefPubMed
5.
go back to reference Nakajima K, Taki J, Tonami N, Hisada K. Decreased 123I-MIBG uptake and increased clearance in various cardiac diseases. Nucl Med Commun. 1994;15:317–23.CrossRefPubMed Nakajima K, Taki J, Tonami N, Hisada K. Decreased 123I-MIBG uptake and increased clearance in various cardiac diseases. Nucl Med Commun. 1994;15:317–23.CrossRefPubMed
6.
go back to reference Bengel FM, Barthel P, Matsunari I, Schmidt G, Schwaiger M. Kinetics of 123I-MIBG after acute myocardial infarction and reperfusion therapy. J Nucl Med. 1999;40:904–10.PubMed Bengel FM, Barthel P, Matsunari I, Schmidt G, Schwaiger M. Kinetics of 123I-MIBG after acute myocardial infarction and reperfusion therapy. J Nucl Med. 1999;40:904–10.PubMed
7.
go back to reference Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol. 2003;41:231–8.CrossRefPubMed Yamada T, Shimonagata T, Fukunami M, Kumagai K, Ogita H, Hirata A, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study. J Am Coll Cardiol. 2003;41:231–8.CrossRefPubMed
9.
go back to reference Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol. 1998;5:579–90.CrossRefPubMed Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol. 1998;5:579–90.CrossRefPubMed
10.
go back to reference Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Hashimoto A, Ogata H. Prognostic implications of an initial loss of cardiac metaiodobenzylguanidine uptake and diabetes mellitus in patients with left ventricular dysfunction. J Card Fail. 2003;9:113–21.CrossRefPubMed Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Hashimoto A, Ogata H. Prognostic implications of an initial loss of cardiac metaiodobenzylguanidine uptake and diabetes mellitus in patients with left ventricular dysfunction. J Card Fail. 2003;9:113–21.CrossRefPubMed
11.
go back to reference Kyuma M, Nakata T, Hashimoto A, Nagao K, Sasao H, Takahashi T, et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med. 2004;45:155–63.PubMed Kyuma M, Nakata T, Hashimoto A, Nagao K, Sasao H, Takahashi T, et al. Incremental prognostic implications of brain natriuretic peptide, cardiac sympathetic nerve innervation, and noncardiac disorders in patients with heart failure. J Nucl Med. 2004;45:155–63.PubMed
12.
go back to reference Matsui T, Tsutamoto T, Maeda K, Kusukawa J, Kinoshita M. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments—comparison with neurohumoral factors. Circ J. 2002;66:537–43.CrossRefPubMed Matsui T, Tsutamoto T, Maeda K, Kusukawa J, Kinoshita M. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments—comparison with neurohumoral factors. Circ J. 2002;66:537–43.CrossRefPubMed
13.
go back to reference Momose M, Kobayashi H, Iguchi N, Matsuda N, Sakomura Y, Kasanuki H, et al. Comparison of parameters of 123I-MIBG scintigraphy for predicting prognosis in patients with dilated cardiomyopathy. Nucl Med Commun. 1999;20:529–35.CrossRefPubMed Momose M, Kobayashi H, Iguchi N, Matsuda N, Sakomura Y, Kasanuki H, et al. Comparison of parameters of 123I-MIBG scintigraphy for predicting prognosis in patients with dilated cardiomyopathy. Nucl Med Commun. 1999;20:529–35.CrossRefPubMed
14.
go back to reference Imamura Y, Fukuyama T, Mochizuki T, Miyagawa M, Watanabe K, Ehime MIBG Heart Failure Study Investigators. Prognostic value of iodine-123-metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. Jpn Circ J. 2001;65:155–60.CrossRefPubMed Imamura Y, Fukuyama T, Mochizuki T, Miyagawa M, Watanabe K, Ehime MIBG Heart Failure Study Investigators. Prognostic value of iodine-123-metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. Jpn Circ J. 2001;65:155–60.CrossRefPubMed
15.
go back to reference Fujimoto S, Amano H, Inoue A, Ishida S, Yamashina S, Yamashina H, et al. Usefulness of 123I-metaiodobenzylguanidine myocardial scintigraphy in the prediction of cardiac events in patients with cardiomyopathy showing stabilization of symptoms or preserved cardiac function. Ann Nucl Med. 2004;18:591–8.CrossRefPubMed Fujimoto S, Amano H, Inoue A, Ishida S, Yamashina S, Yamashina H, et al. Usefulness of 123I-metaiodobenzylguanidine myocardial scintigraphy in the prediction of cardiac events in patients with cardiomyopathy showing stabilization of symptoms or preserved cardiac function. Ann Nucl Med. 2004;18:591–8.CrossRefPubMed
16.
go back to reference Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Randé JL, Duval AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med. 1999;40:917–23.PubMed Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Randé JL, Duval AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med. 1999;40:917–23.PubMed
17.
go back to reference Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging. 2008;35:535–46.CrossRefPubMed Agostini D, Verberne HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging. 2008;35:535–46.CrossRefPubMed
18.
go back to reference Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29:1147–59.CrossRefPubMed Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29:1147–59.CrossRefPubMed
19.
go back to reference Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34.
20.
go back to reference Petitti DB. Meta-analysis, decision analysis, and cost-effective analysis. New York: Oxford University Press; 2000. p. 117–8. Petitti DB. Meta-analysis, decision analysis, and cost-effective analysis. New York: Oxford University Press; 2000. p. 117–8.
21.
go back to reference Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;15(21):1539–58.CrossRef Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;15(21):1539–58.CrossRef
22.
go back to reference Knickmeier M, Matheja P, Wichter T, Schäfers KP, Kies P, Breithardt G, et al. Clinical evaluation of no-carrier-added meta-[123I]iodobenzylguanidine for myocardial scintigraphy. Eur J Nucl Med. 2000;27:302–7.CrossRefPubMed Knickmeier M, Matheja P, Wichter T, Schäfers KP, Kies P, Breithardt G, et al. Clinical evaluation of no-carrier-added meta-[123I]iodobenzylguanidine for myocardial scintigraphy. Eur J Nucl Med. 2000;27:302–7.CrossRefPubMed
23.
go back to reference Farahati J, Bier D, Scheubeck M, Lassmann M, Schelper LF, Grelle I, et al. Effect of specific activity on cardiac uptake of iodine-123-MIBG. J Nucl Med. 1997;38:447–51.PubMed Farahati J, Bier D, Scheubeck M, Lassmann M, Schelper LF, Grelle I, et al. Effect of specific activity on cardiac uptake of iodine-123-MIBG. J Nucl Med. 1997;38:447–51.PubMed
24.
go back to reference Verberne HJ, Habraken JB, van Eck-Smit BL, Agostini D, Jacobson AF. Variations in 123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation. Eur J Nucl Med Mol Imaging. 2008;35:547–53.CrossRefPubMed Verberne HJ, Habraken JB, van Eck-Smit BL, Agostini D, Jacobson AF. Variations in 123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation. Eur J Nucl Med Mol Imaging. 2008;35:547–53.CrossRefPubMed
25.
go back to reference Nakajima K. Normal values for nuclear cardiology: Japanese databases for myocardial perfusion, fatty acid and sympathetic imaging and left ventricular function. Ann Nucl Med. 2010;24(3):125–35.CrossRefPubMed Nakajima K. Normal values for nuclear cardiology: Japanese databases for myocardial perfusion, fatty acid and sympathetic imaging and left ventricular function. Ann Nucl Med. 2010;24(3):125–35.CrossRefPubMed
26.
go back to reference Yamashina S, et al. Role of MIBG myocardial scintigraphy in the assessment of heart failure: the need to establish evidence. Eur J Nucl Med Mol Imaging. 2004;31:1353. Yamashina S, et al. Role of MIBG myocardial scintigraphy in the assessment of heart failure: the need to establish evidence. Eur J Nucl Med Mol Imaging. 2004;31:1353.
Metadata
Title
Determination of the survival rate in patients with congestive heart failure stratified by 123I-MIBG imaging: a meta-analysis from the studies performed in Japan
Authors
Yoichi Kuwabara
Nagara Tamaki
Tomoaki Nakata
Shohei Yamashina
Junichi Yamazaki
Publication date
01-02-2011
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 2/2011
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-010-0452-0

Other articles of this Issue 2/2011

Annals of Nuclear Medicine 2/2011 Go to the issue